Featuring the highest resolution detector in the industry,
VersaVision sets the standard for specimen visualization and verification
TUCSON, Ariz.--(BUSINESS WIRE)--Faxitron, a global leader in best-in-class imaging systems for medicine
and life science research, today announced that the U.S. Food and Drug
Administration (FDA) has granted 510(k) clearance to VersaVision for
radiographic imaging of core biopsies and surgically excised specimens.
VersaVision is the company’s newest cabinet x-ray system. It delivers
People are also reading…
instant imaging and verification of samples with unparalleled imaging
resolution, facilitating an improved clinical experience for both
providers and patients.
The launch of VersaVision signifies a breakthrough in the development of
high-resolution imaging technologies, as the system features a
proprietary 21 lp/mm detector that enables up to 5X geometric
magnification. Faxitron is the only dedicated specimen imaging company
that designs and produces its own detectors, which are the key
components of radiographic imaging systems, at its factory in Tucson,
Arizona. This enables the highest level of imaging quality control. As
such, VersaVision is setting a higher standard for quality and clarity
in the industry.
Moreover, VersaVision ensures an uninterrupted workflow in the clinical
setting as radiologists now have the opportunity to access an intuitive
system that delivers optimal resolution, faster image acquisition and
the ability to image a wide range of specimens. Such improvements in
imaging technology not only impact day-to-day operations in radiology,
but may subsequently benefit healthcare staff and patients as well. By
reducing procedural and verification time, VersaVision may help expedite
a more confident diagnosis and a smoother patient experience.
“At Faxitron, we are committed to improving the standard of care for
breast cancer diagnosis and treatment,” said Donogh O’Driscoll, CFO and
COO of Faxitron. “VersaVision is the latest addition to our
comprehensive portfolio of imaging solutions that showcases our
continued investment in technology and innovation. With a best-in-class
high-resolution detector that provides an exceptional 21 lp/mm spatial
resolution within a 12”x15” field of view, VersaVision has the potential
to reduce the number of patient recalls and re-excision rates—ultimately
moving us forward in our mission to help healthcare providers achieve
their vision for better care and better patient outcomes.”
For more information about VersaVision, visit www.faxitron.com/product/versavision.
About Faxitron® Bioptics, LLC
As a global leader and pioneer for best-in-class digital imaging
systems, Faxitron is dedicated to helping healthcare providers and
researchers achieve their vision for a better, healthier world at large.
Through the continuous innovation and advancement of imaging
technologies, Faxitron aims to elevate the standard of care in medicine
and the standard of quality in life science research. With applications
spanning from breast surgery to pathology imaging, and from biological
irradiation and preclinical imaging to non-destructive testing, Faxitron
is building a comprehensive portfolio of solutions that sets new
standards for precision and quality in the industry. For more
information, visit www.faxitron.com.
Contacts
Partners & Simons for Faxitron
Kelcie Chambers, 706-951-8865